The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001024336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/07/2026
Date registered
Help: Date registered
19/08/2026
Date last updated
Help: Date last updated
19/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/08/2026
Date results provided
Help: Date results provided
19/08/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A pilot study of coconut oil mouthwash for oral mucositis in children receiving cancer treatment
Scientific title
A randomized feasibility trial of coconut oil mouthwash for mucositis in pediatric oncology patients
Additional trial identifiers [1] 317984 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Oral mucositis 343022 0
Children's cancer 343115 0
Condition category
Condition code
Cancer 339116 339116 0 0
Children's - Leukaemia & Lymphoma
Cancer 339117 339117 0 0
Children's - Brain
Cancer 339118 339118 0 0
Children's - Other
Oral and Gastrointestinal 339203 339203 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants randomized 1:1 to receive either routine chlorhexidine 0.2% 5ml mouthwash four times daily (control) or chlorhexidine plus two additional virgin coconut oil 5ml mouthwashes daily (intervention) during one cycle of chemotherapy. Safety, feasibility, compliance and episodes of oral mucositis are assessed using daily e-Diary, to be completed by the parent. Oral microbial swabs are collected for qualitative and quantitative microbial profiling at three timepoints during the study; baseline, one week into chemotherapy cycle and one week after completion of chemotherapy cycle. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Intervention code [1] 334891 0
Prevention
Intervention code [2] 334892 0
Treatment: Drugs
Description of the comparator or control
Participants in the control arm received standard of care regimen using four times daily chlorhexidine 0.2% mouthwash. Compliance and episodes of oral mucositis are assessed using daily e-Diary over the course of one cycle of chemotherapy.
Control group
Active

Outcomes
Primary outcome [1] 346352 0
Safety
Timepoint [1] 346352 0
Daily during one cycle of chemotherapy. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Primary outcome [2] 346353 0
Feasibility
Timepoint [2] 346353 0
Daily during the course of one cycle of chemotherapy. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Primary outcome [3] 346537 0
Feasibility
Timepoint [3] 346537 0
Daily during the course of one cycle of chemotherapy. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Secondary outcome [1] 465504 0
Changes to oral microbiome
Timepoint [1] 465504 0
Baseline, one week into chemotherapy cycle and one week following completion of chemotherapy cycle. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Secondary outcome [2] 466280 0
Tolerability
Timepoint [2] 466280 0
Daily during the course of one cycle of chemotherapy. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).
Secondary outcome [3] 466281 0
Number of episodes, duration and severity of oral mucositis
Timepoint [3] 466281 0
Daily during the course of one cycle of chemotherapy. Chemotherapy cycle duration varies depending on condition and treatment protocol, however average 28 days (range 3-8 weeks).

Eligibility
Key inclusion criteria
Patients aged 6-16 years, receiving treatment for an oncological condition, free of severe infection, and undergoing a chemotherapy cycle expected to result in a neutrophil count of <0.5x109/L, when mucositis is more likely to occur
Minimum age
6 Years
Maximum age
16 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Non-compliance risk, allogeneic transplant or autologous stem cell rescue, maintenance therapy for acute lymphoblastic leukemia, and known allergies to coconut oil

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
1:1 ratio using the Research Entry Data Capture (REDCap) database, without stratification for sex or age
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29916 0
Perth Children's Hospital - Nedlands
Recruitment postcode(s) [1] 46273 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 322534 0
Hospital
Name [1] 322534 0
Perth Children's Hospital
Country [1] 322534 0
Australia
Funding source category [2] 322571 0
Government body
Name [2] 322571 0
Western Australian Near Miss Awards Grant
Country [2] 322571 0
Australia
Primary sponsor type
Government body
Name
Child and Adolescent Health Service Western Australia
Address
Country
Australia
Secondary sponsor category [1] 325495 0
Charities/Societies/Foundations
Name [1] 325495 0
The Kids Research Institute Australia
Address [1] 325495 0
Country [1] 325495 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321016 0
Child and Adolescent Health Service Human Research Ethics Committee
Ethics committee address [1] 321016 0
Ethics committee country [1] 321016 0
Australia
Date submitted for ethics approval [1] 321016 0
16/06/2022
Approval date [1] 321016 0
29/08/2022
Ethics approval number [1] 321016 0
RGS0000005526

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152378 0
Prof Nick Gottardo
Address 152378 0
Department of Haematology, Oncology and Bone Marrow Transplant, Perth Children’s Hospital, 15 Hospital Avenue, Nedlands, WA 6009
Country 152378 0
Australia
Phone 152378 0
+61 8 6456 4430
Fax 152378 0
Email 152378 0
Contact person for public queries
Name 152379 0
Nick Gottardo
Address 152379 0
Department of Haematology, Oncology and Bone Marrow Transplant, Perth Children’s Hospital, 15 Hospital Avenue, Nedlands, WA 6009
Country 152379 0
Australia
Phone 152379 0
+61 8 6456 4430
Fax 152379 0
Email 152379 0
Contact person for scientific queries
Name 152380 0
Nick Gottardo
Address 152380 0
Department of Haematology, Oncology and Bone Marrow Transplant, Perth Children’s Hospital, 15 Hospital Avenue, Nedlands, WA 6009
Country 152380 0
Australia
Phone 152380 0
+61 8 6456 4430
Fax 152380 0
Email 152380 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
A finite period of: 7 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ProtocolNo Coconut oil for oral mucositis PROTOCOL v3 1AUG2022.docx
Basic resultsNo ANZCTR Basic Results.docx

Documents added automatically
No additional documents have been identified.